{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.9","value":"124"},{"groupId":"OG001","spread":"64.4","value":"280"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Cmax was defined as the maximum concentration observed after the first infusion calculated using the non-compartmental analysis.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Isatuximab 10 mg/kg IV infusion QW for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1), and then Q2W (i.e., on Day 1 and 15) for subsequent treatment cycles (each cycle of 28 days) until unacceptable AEs, disease progression, or any other reason for discontinuation whichever occurs first (maximum duration of exposure: 112 weeks).","id":"OG000","title":"Phase 1, Cohort 1: Isatuximab 10 mg/kg"},{"description":"Participants received Isatuximab 20 mg/kg IV infusion, QW for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1), and then Q2W (i.e., on Day 1 and 15) for subsequent treatment cycles (each cycle of 28 days) until unacceptable AEs, disease progression, or any other reason for discontinuation whichever occurs first (maximum duration of exposure: 137 weeks).","id":"OG001","title":"Phase 1, Cohort 2: Isatuximab 20 mg/kg"}],"paramType":"MEAN","populationDescription":"Analysis was performed on PK population. Here, \"Overall number of participants analyzed\" = participants with available data for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 at 0 hour (pre-dose), mid-infusion (2 hours post-infusion), end of infusion (EOI) and EOI+4-hour, Day 2 (24 hour), Day 3 (48 hour), Day 4 (72 hour) and pre-dose on Day 8 (0 hour)","title":"Phase 1: Maximum Observed Concentration (Cmax) After First Infusion of Isatuximab","type":"SECONDARY","unitOfMeasure":"micrograms per milliliter"}